Cargando…
Treatment Approaches to Chronic Lymphocytic Leukemia With High-Risk Molecular Features
The clinical course of chronic lymphocytic leukemia (CLL) is highly variable. Over the past decades, several cytogenetic, immunogenetic and molecular features have emerged that identify patients suffering from CLL with high-risk molecular features. These biomarkers can clearly aid prognostication, b...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8695615/ https://www.ncbi.nlm.nih.gov/pubmed/34956898 http://dx.doi.org/10.3389/fonc.2021.780085 |
_version_ | 1784619619929030656 |
---|---|
author | van der Straten, Lina Hengeveld, Paul J. Kater, Arnon P. Langerak, Anton W. Levin, Mark-David |
author_facet | van der Straten, Lina Hengeveld, Paul J. Kater, Arnon P. Langerak, Anton W. Levin, Mark-David |
author_sort | van der Straten, Lina |
collection | PubMed |
description | The clinical course of chronic lymphocytic leukemia (CLL) is highly variable. Over the past decades, several cytogenetic, immunogenetic and molecular features have emerged that identify patients suffering from CLL with high-risk molecular features. These biomarkers can clearly aid prognostication, but may also be capable of predicting the efficacy of various treatment strategies in subgroups of patients. In this narrative review, we discuss treatment approaches to CLL with high-risk molecular features. Specifically, we review and provide a comprehensive overview of clinical trials evaluating the efficacy of chemotherapy, chemoimmunotherapy and novel agent-based treatments in CLL patients with TP53 aberrations, deletion of the long arm of chromosome 11, complex karyotype, unmutated IGHV, B cell receptor stereotypy, and mutations in NOTCH1 or BIRC3. Furthermore, we discuss future pharmaceutical and immunotherapeutic perspectives for CLL with high-risk molecular features, focusing on agents currently under investigation in clinical trials. |
format | Online Article Text |
id | pubmed-8695615 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86956152021-12-24 Treatment Approaches to Chronic Lymphocytic Leukemia With High-Risk Molecular Features van der Straten, Lina Hengeveld, Paul J. Kater, Arnon P. Langerak, Anton W. Levin, Mark-David Front Oncol Oncology The clinical course of chronic lymphocytic leukemia (CLL) is highly variable. Over the past decades, several cytogenetic, immunogenetic and molecular features have emerged that identify patients suffering from CLL with high-risk molecular features. These biomarkers can clearly aid prognostication, but may also be capable of predicting the efficacy of various treatment strategies in subgroups of patients. In this narrative review, we discuss treatment approaches to CLL with high-risk molecular features. Specifically, we review and provide a comprehensive overview of clinical trials evaluating the efficacy of chemotherapy, chemoimmunotherapy and novel agent-based treatments in CLL patients with TP53 aberrations, deletion of the long arm of chromosome 11, complex karyotype, unmutated IGHV, B cell receptor stereotypy, and mutations in NOTCH1 or BIRC3. Furthermore, we discuss future pharmaceutical and immunotherapeutic perspectives for CLL with high-risk molecular features, focusing on agents currently under investigation in clinical trials. Frontiers Media S.A. 2021-12-09 /pmc/articles/PMC8695615/ /pubmed/34956898 http://dx.doi.org/10.3389/fonc.2021.780085 Text en Copyright © 2021 van der Straten, Hengeveld, Kater, Langerak and Levin https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology van der Straten, Lina Hengeveld, Paul J. Kater, Arnon P. Langerak, Anton W. Levin, Mark-David Treatment Approaches to Chronic Lymphocytic Leukemia With High-Risk Molecular Features |
title | Treatment Approaches to Chronic Lymphocytic Leukemia With High-Risk Molecular Features |
title_full | Treatment Approaches to Chronic Lymphocytic Leukemia With High-Risk Molecular Features |
title_fullStr | Treatment Approaches to Chronic Lymphocytic Leukemia With High-Risk Molecular Features |
title_full_unstemmed | Treatment Approaches to Chronic Lymphocytic Leukemia With High-Risk Molecular Features |
title_short | Treatment Approaches to Chronic Lymphocytic Leukemia With High-Risk Molecular Features |
title_sort | treatment approaches to chronic lymphocytic leukemia with high-risk molecular features |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8695615/ https://www.ncbi.nlm.nih.gov/pubmed/34956898 http://dx.doi.org/10.3389/fonc.2021.780085 |
work_keys_str_mv | AT vanderstratenlina treatmentapproachestochroniclymphocyticleukemiawithhighriskmolecularfeatures AT hengeveldpaulj treatmentapproachestochroniclymphocyticleukemiawithhighriskmolecularfeatures AT katerarnonp treatmentapproachestochroniclymphocyticleukemiawithhighriskmolecularfeatures AT langerakantonw treatmentapproachestochroniclymphocyticleukemiawithhighriskmolecularfeatures AT levinmarkdavid treatmentapproachestochroniclymphocyticleukemiawithhighriskmolecularfeatures |